Citations

Clear

30 citation(s) found for "SPIROMICS".

Associations of COPD and Related Outcomes With COVID-19 Hospitalization or Death: The C4R, Copdgene, and Spiromics Studies
Rusk, A.M., Bowler, R.P., Margaret, D., Elkind, Mitchell S.V. , Ramachandran, V., Woodruff, Prescott G. , Garudadri, S., McKleroy, William , Ortega, Victor E. , Balte, Pallavi , Allen, Norrina B. , Barr, R. Graham , Regan, Elizabeth Anne , Cole, Shelley A. , Couper, David , Demmer, Ryan T. , Kaplan, Robert C. , Lee, Joyce , Post, Wendy S. , Ramachandran, V., Schwartz, David A. , Tracy, Russell P. , Wenzel, Sally E. , Xanthakis, Vanessa , Make, Barry J. , Oelsner, Elizabeth C.

Mayo Clinic

C107. MICROBIAL RESPIRATORY INFECTIONS DISCOVERIES | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A6817-A6817

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6817 Get It

Air Pollution Exposure and Interstitial Lung Features in SPIROMICS Participants with Chronic Obstructive Pulmonary Disease
Baddour, Nicolas A. , Gassett, Amanda J. , Woo, Han, Hoffman, Eric A. , Newell, John D. , Woodruff, Prescott G. , Pirozzi, C.S. , O’Neal, Wanda K. , Peters, Stephen P. , Hastie, Annette T. , Hansel, Nadia N. , Ortega, Victor E. , Kaufman, Joel D. , Sack, Coralynn , Hoffman, Eric A , Hastie, Annette T , Kaufman, Joel D , O'Neal, Wanda K , Paulin, Laura M. , Barjaktarević, Igor , Barr, R. Graham , Han, MeiLan King , Martínez, Fernando J.

Mayo Clinic

Annals of the American Thoracic Society | April 3, 2024 | Volume: 21 | Issue: 9 | Pages: 1251-1260

10.1513/annalsats.202308-741oc | PMID 38568439 Get It

Abstract Rationale It is unknown whether air pollution is associated with radiographic features of interstitial lung disease in individuals with chronic obstructive pulmonary disease (COPD). Objectives To determine whether air pollution increases the prevalence of interstitial lung abnormalities (ILA) or percent high-attenuation areas (HAA) on computed tomography (CT) in individuals with a heavy smoking history and COPD. Methods We performed a cross-sectional study of SPIROMICS (Subpopulations and Intermediate Outcome Measures in COPD Study), focused on current or former smokers with COPD. Ten-year exposure to particulate matter ⩽2.5 μm in aerodynamic diameter (PM2.5), nitrogen oxides (NOx), nitrogen dioxide (NO2), and ozone before enrollment CT (completed between 2010 and 2015) were estimated with validated spatiotemporal models at residential addresses. We applied adjusted multivariable modified Poisson regression and linear regression to investigate associations between pollution exposure and relative risk (RR) of ILA or increased percent HAA (between −600 and −250 Hounsfield units), respectively. We assessed for effect modification by MUC5B-promoter polymorphism (variant allele carriers GT or TT vs. GG at rs3705950), smoking status, sex, and percent emphysema. Results Among 1,272 participants with COPD assessed for HAA, 424 were current smokers, and 249 were carriers of the variant MUC5B allele. A total of 519 participants were assessed for ILA. We found no association between pollution exposure and ILA or HAA. Associations between pollutant exposures and risk of ILA were modified by the presence of MUC5B polymorphism (P value interaction term for NOx = 0.04 and PM2.5 = 0.05) and smoking status (P value interaction term for NOx = 0.05; NO2 = 0.01; and ozone = 0.05). With higher exposure to NOx and PM2.5, MUC5B variant carriers had an increased risk of ILA (RR per 26 ppb NOx, 2.41; 95% confidence interval [CI], 0.97–6.0; and RR per 4 μg ⋅ m−3 PM2.5, 1.43; 95% CI, 0.93–2.2, respectively). With higher exposure to NO2, former smokers had an increased risk of ILA (RR per 10 ppb, 1.64; 95% CI, 1.0–2.7). Conclusions Exposure to ambient air pollution was not associated with interstitial features on CT in this population of heavy smokers with COPD. MUC5B modified the association between pollution and ILA, suggesting that gene–environment interactions may influence prevalence of interstitial lung features in COPD.
The Effect of Chronic Altitude Exposure on Chronic Obstructive Pulmonary Disease Outcomes in the SPIROMICS Cohort: An Observational Cohort Study
Suri, Rajat , Markovic, Daniela , Woo, Han, Arjomandi, Mehrdad , Bowler, Russell P. , Criner, Gerard J. , Curtis, Jeffrey L. , Dransfield, Mark T. , Fortis, Spyridon , Hoffman, Eric A. , Kaufman, Joel D. , Ortega, Victor E. , Paine, Robert, Soler, Xavier , Woodruff, Prescott G. , Hansel, Nadia N. , Cooper, Christopher B. , Bowler, Russell P , Criner, Gerard , Curtis, Jeffrey L , Dransfield, Mark T , Drummond, M Bradley , Fortis, Spyridon , Han, MeiLan King , Hoffman, Eric A , Kaner, Robert J. , Kaufman, Joel D , Krishnan, Jerry A , Martinez, Fernando , Ohar, Jill , Woodruff, Prescott G , Hansel, Nadia N , Cooper, Christopher B , Tashkin, Donald , Buhr, Russell G , Barjaktarevic, Igor , Barr, R. Graham , Drummond, Michael , Martínez, Fernando J. , Tashkin, Donald P. , Buhr, Russell G. , Barjaktarević, Igor

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | March 20, 2024 | Volume: 210 | Issue: 10 | Pages: 1210-1218

10.1164/rccm.202310-1965oc | PMID 38507607 Get It

Abstract Rationale Individuals with chronic obstructive pulmonary disease (COPD) have airflow obstruction and maldistribution of ventilation. For those living at high altitude, any gas exchange abnormality is compounded by reduced partial pressures of inspired oxygen. Objectives Does residence at higher altitude exposure affect COPD outcomes, including lung function, imaging characteristics, symptoms, health status, functional exercise capacity, exacerbations, and mortality? Methods From the SPIROMICS (Subpopulation and Intermediate Outcome Measures in COPD Study) cohort, we identified individuals with COPD living below 1,000 ft (305 m) elevation (n = 1,367) versus above 4,000 ft (1,219 m) elevation (n = 288). Multivariable regression models were used to evaluate associations of exposure to high altitude with COPD-related outcomes. Measurements and Main Results Living at higher altitude was associated with reduced functional exercise capacity as defined by 6-minute-walk distance (−32.3 m [95% confidence interval, −49.8 to −14.8 m]). There were no differences in patient-reported outcomes as defined by symptoms (COPD Assessment Test and modified Medical Research Council dyspnea scale), or health status (St. George’s Respiratory Questionnaire). Higher altitude was not associated with a different rate of FEV1 decline. Higher altitude was associated with lower odds of severe exacerbations (incidence rate ratio, 0.65 [95% confidence interval, 0.46 to 0.90]). There were no differences in small airway disease, air trapping, or emphysema. In longitudinal analyses, higher altitude was associated with increased mortality (hazard ratio, 1.25 [95% confidence interval, 1.0 to 1.55]); however, this association was no longer significant when accounting for air pollution. Conclusions Long-term altitude exposure is associated with reduced functional exercise capacity in individuals with COPD, but this did not translate into differences in symptoms or health status. In addition, long-term high-altitude exposure did not affect progression of disease as defined by longitudinal changes in spirometry. Clinical trial registered with www.clinicaltrials.gov (NCT 01969344).
Longitudinal Analysis of Clinical Outcomes in PiMZ Alpha-1 Antitrypsin Smokers From the Spiromics Cohort
HIXSON, ROXANA, Zhuang, Zhaohan, Markovic, D., Barr, R.G., Cooper, C.B. , Curtis, J.L., Hawkins, G.A., Hoffman, E.A., Kim, V., Martinez, F.J., Paine, Robert , Pirozzi, C.S. , Wells, James M. , Woodruff, Prescott G. , Tashkin, Donald P., Bleecker, Eugene R., Meyers, Deborah A. , Ortega, Victor E. , Barjaktarević, Igor , Buhr, Russell G. , Curtis, J.L., Drummond, Michael , Fortis, Spyridon , Hawkins, G.A., Han, MeiLan King , Hoffman, E.A., Manichaikul, Ani , Pottinger, Tess D. , Wells, J.M.

Mayo Clinic

B22. NEW TREATMENTS AND NOVEL TARGETS FOR COPD AND ALPHA-1 | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A2840-A2840

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2840 Get It

Deep Residual Convolutional Network Predicts Future Severe Exacerbations of COPD in SPIROMICS
Awan, Hira A. , Chaudhary, Muhammad F. A. , Bhatt, S.P. , Cooper, C.B., Criner, G.J., Hansel, N.N., Krishnan, J.A., Ortega, Victor E. , Paine, Robert , Schroeder, Joyce , Gerard, Sarah E. , Comellas, Alejandro P. , Hoffman, Eric A. , Barjaktarević, Igor , Bhatt, Surya P. , Cooper, C.B. , Criner, G.J., Reinhardt, Joseph M.

Mayo Clinic

B41. RISK FACTORS AND OUTCOMES FOR COPD EXACERBATIONS | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A3318-A3318

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a3318 Get It

Loss of Airway Bacterial Phylogenetic Diversity in Mild to Moderate COPD Associates With Clinical and Pathobiological Markers of Disease Development
Huang, Yuanding , Opron, Kristopher, Begley, Lesa, Erb‐Downward, John R. , Alexis, N.E. , Bowler, R.P., Christenson, S., Cooper, C.B. , Hansel, Nadia N. , Hastie, Annette T. , Martinez, F.J., Ortega, Victor E. , Peters, S.P., Paine, Robert , Woodruff, P., SPIROMICS, Li, G., Barjaktarević, Igor , Barr, R. Graham , Boucher, Richard C. , Comellas, Alejandro P. , Couper, David , Han, MeiLan King , Kaner, Robert J. , Kesımer, Mehmet , Huffnagle, Gary B. , Curtis, Jeffrey L.

Mayo Clinic

B94. DISEASE PROGRESSION AND MORBIDITY ALONG THE SPECTRUM OF COPD: FROM EARLY TO ESTABLISHED | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A4203-A4203

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a4203 Get It

Prolonged, physiologically relevant nicotine concentrations in the airways of smokers
Esther, Charles R. , O’Neal, Wanda K. , Alexis, Neil E. , Koch, Abigail L. , Cooper, Christopher B. , Raffield, Laura M. , Bowler, Russel P., Comellas, Alejandro P. , Peters, Stephen P. , Hastie, Annette T. , Ronish, Bonnie , Ortega, Victor E. , Wells, J. Michael , Halper‐Stromberg, Eitan , Rennard, Stephen I. , Boucher, Richard C. , SPIROMICS, on behalf of, Hastie, Annette T , Curtis, Jeffrey L , Ronish, Bonnie , Boucher, Richard C , Raffield, Laura M , O'Neal, Wanda K , Comellas, Alejandro P , Wells, J Michael , Barjaktarević, Igor , Curtis, Jeffrey L. , SPIROMICS, on behalf of

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | November 7, 2022 | Volume: 324 | Issue: 1 | Pages: L32-L37

10.1152/ajplung.00038.2022 | PMID 36342131 Get It

Nicotine from cigarette smoke is a biologically active molecule that has pleiotropic effects in the airway, which could play a role in smoking-induced lung disease. However, whether nicotine and its metabolites reach sustained, physiologically relevant concentrations on airway surfaces of smokers is not well defined. To address these issues, concentrations of nicotine, cotinine, and hydroxycotinine were measured by mass spectrometry (MS) in supernatants of induced sputum obtained from participants in the subpopulations and intermediate outcome measures in COPD study (SPIROMICS), an ongoing observational study that included never smokers, former smokers, and current smokers with and without chronic obstructive pulmonary disease (COPD). A total of 980 sputum supernatants were analyzed from 77 healthy never smokers, 494 former smokers (233 with COPD), and 396 active smokers (151 with COPD). Sputum nicotine, cotinine, and hydroxycotinine concentrations corresponded to self-reported smoking status and were strongly correlated to urine measures. A cutoff of ∼8–10 ng/mL of sputum cotinine distinguished never smokers from active smokers. Accounting for sample dilution during processing, active smokers had airway nicotine concentrations in the 70–850 ng/mL (∼0.5–5 µM) range, and concentrations remained elevated even in current smokers who had not smoked within 24 h. This study demonstrates that airway nicotine and its metabolites are readily measured in sputum supernatants and can serve as biological markers of smoke exposure. In current smokers, nicotine is present at physiologically relevant concentrations for prolonged periods, supporting a contribution to cigarette-induced airway disease.